about
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaCancer of the larynx--treatment results after primary radiotherapy with salvage surgery in a series of 1005 patients.A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.A placebo-controlled, blinded and randomised study on the effects of recombinant human thyrotropin on quality of life in the treatment of thyroid cancer.Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Motesanib diphosphate in progressive differentiated thyroid cancer.Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialA phase II study of thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response.A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.Immunotherapy of distant metastatic disease.Surgery and radiotherapy in the treatment of cutaneous melanomaEffect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.Small molecules and targeted therapies in distant metastatic disease.How to improve cytotoxic therapy in advanced breast cancer.Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline.The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials.Trends in melanoma in the elderly in Denmark, 1980-2012.More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries.Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyThe role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients.Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma.Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.Total Thyroidectomy for Thyroid Cancer Followed by Thyroid Storm due to Thyrotropin Receptor Antibody Stimulation of Metastatic Thyroid TissueLarge discrepancy in the results of sensitive measurements of thyroglobulin antibodies in the follow-up on thyroid cancer: a diagnostic dilemma.Prognostic stratification of ulcerated melanoma: not only the extent matters.A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.Hypopharyngeal cancer: results of treatment based on radiation therapy and salvage surgery.A phase II study of thalidomide in patients with brain metastases from malignant melanoma.Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites.Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b.
P50
Q29615443-EAF7B5A1-0753-41F6-A398-190B1BFC5AAAQ30702610-87D48AB8-92F5-46B4-9ECE-255537D74215Q33368865-4D916625-E294-4B0D-9C2A-633874BCE819Q33393763-032A65E7-20D5-4CA0-AD14-6D875A29B9F2Q33464837-31CE28CB-EE15-437B-BEC2-4EA1F1F1A26AQ33597636-92E8F0E7-9990-4639-822B-6C086036A3B1Q34265391-65AF180B-55E9-447C-A3C2-C7B325B57868Q34487294-E0EE18F0-BF05-4A52-B77C-29CCB603004CQ34633455-2F8A2AC1-107A-452B-A23E-0275C78E2A01Q34791480-5E9262FD-5A80-4DDC-AFD7-68CCA337302DQ34989774-7FC2AE3C-91CD-4129-A5E6-DF3697F4F126Q35195766-36A9E436-6047-4708-8646-89A0234AD748Q35602183-1F238294-5A51-4648-8609-53E4FDA8628EQ35617517-0C818D91-8630-4D4D-A1DB-D78F4C83E80AQ35989186-6622A685-98A4-41B2-9436-92DD2434558AQ36615128-9648BDB8-F247-430A-8E96-CC06A733D964Q37266668-ADCA4100-00B3-494A-8D25-040A0E24F68DQ37266677-D49441CD-ACB6-4537-816D-4E8CB2817438Q37387829-6C3CBC52-E4E6-4CFB-BC92-D47E935015BEQ37555793-AEAD7EDD-D28C-48AC-9041-8D0251E39976Q37938316-4500CB39-FB9A-4779-AD4C-11D64561ED1EQ38563536-F5CA35C1-2178-4C98-8EA5-022412FACD60Q38881585-678E3739-E4F8-4470-AB70-FD9D337E523AQ38918842-62D9836F-B089-4A75-8BA8-53F7C46651ECQ38926324-A790131E-CCB8-4D25-A78D-05B30A3CF098Q39177952-9E3042E5-3033-4CA2-80C2-72232B79818CQ39311439-47084D4A-B3DA-47FE-9BAF-0D310328C4CBQ39317681-326357B8-46D0-471D-ADE6-955E0F233396Q40180453-448660C8-C4F4-4EA8-B9F2-CB4F22310925Q40671706-5A93690F-2C27-4D58-AB25-D4630D394B0DQ42668018-DA7408EF-23F9-4F86-B691-26175C06CC41Q42916972-56B5EDF9-1B48-477D-B805-923C9ECBD333Q43687490-0AD09010-CB57-466B-B257-36D7209774C8Q44230885-1A5F1D8E-EAD7-4AC6-BFC0-9E3450C1C770Q44705099-C5477F0E-39B9-4DDE-B7BE-950FAD332D5FQ44981756-765A99A6-4669-402F-975D-385A4E4AEE14Q46496647-7F1C6B96-B62C-48A4-967F-601E1CD48FE8Q46546767-761816F4-1D86-49E4-89C9-897EFBEFB69CQ47223030-3E9CA395-EF0C-493B-8BBA-310BB35D2FEBQ48511909-2FB2FE8B-7047-4ED5-80C9-E04E3F4E5B71
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Lars Bastholt
@ast
Lars Bastholt
@en
Lars Bastholt
@es
Lars Bastholt
@nl
type
label
Lars Bastholt
@ast
Lars Bastholt
@en
Lars Bastholt
@es
Lars Bastholt
@nl
prefLabel
Lars Bastholt
@ast
Lars Bastholt
@en
Lars Bastholt
@es
Lars Bastholt
@nl
P106
P1153
6603761641
P21
P214
208147905250479091542
P31
P496
0000-0001-5478-9826
P735
P7859
viaf-208147905250479091542